866-997-4948(US-Canada Toll Free)

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 56 Pages

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2017'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

The report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2017' outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Immunology and Musculoskeletal Disorders which include indications Critical Limb Ischemia, Achondroplasia, Age Related Macular Degeneration, Bone Disorders, Breast Cancer, Cancer Pain, Diabetic Macular Edema, Fibrosis, Hepatocellular Carcinoma, Intermittent Claudication, Melanoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Proliferative Diabetic Retinopathy (PDR), Prostate Cancer, Retinal Vein Occlusion, Rheumatoid Arthritis, Solid Tumor and Wet (Neovascular / Exudative) Macular Degeneration.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
- The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview 7
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment 16
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development 22
ID Pharma Co Ltd 22
Kringle Pharma Inc 22
Ohr Pharmaceutical Inc 23
Ribomic Inc 23
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles 24
Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
CT-400 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CT-400P - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
DVC-10101 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
NK-4 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
RBM-007 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
squalamine lactate - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
TR-764 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products 41
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products 43
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones 44
Featured News & Press Releases 44
Apr 10, 2017: Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD 44
May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee 44
Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA 45
Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program 45
Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program 46
Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting 46
Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology 47
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 48
May 07, 2015: Ohr Pharmaceutical Presents Data From OHR-102 Phase II IMPACT Study in Wet-AMD at ARVO Conference 49
Apr 30, 2015: Ohr Pharmaceutical to Present at the 2015 Association for Research in Vision and Ophthalmology Conference in Denver, CO 50
Mar 27, 2015: Ohr Pharmaceutical Announces Final Topline Data From OHR-102 Phase II IMPACT Study in Wet-AMD 50
Mar 02, 2015: Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting 51
Oct 20, 2014: Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting 52
Oct 14, 2014: Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD 53
Oct 07, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 11
Number of Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 13
Number of Products under Investigation by Universities/Institutes, H2 2017 14
Products under Investigation by Universities/Institutes, H2 2017 15
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 19
Number of Products by Stage and Molecule Type, H2 2017 21
Pipeline by ID Pharma Co Ltd, H2 2017 22
Pipeline by Kringle Pharma Inc, H2 2017 22
Pipeline by Ohr Pharmaceutical Inc, H2 2017 23
Pipeline by Ribomic Inc, H2 2017 23
Dormant Products, H2 2017 41
Dormant Products, H2 2017 (Contd..1), H2 2017 42
Discontinued Products, H2 2017 43

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Routes of Administration, H2 2017 18
Number of Products by Stage and Routes of Administration, H2 2017 18
Number of Products by Molecule Types, H2 2017 20
Number of Products by Stage and Molecule Types, H2 2017 20

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *